The influence of drug-like concepts on decision-making in medicinal chemistry
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development. However, despite this acceptance, analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. The consequences of the marked increase in lipophilicity--the most important drug-like physical property--include a greater likelihood of lack of selectivity and attrition in drug development. Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(Note that liophilicity per se may not be relevant, as drugs require carriers to cross membranes [18], and promiscuity and off-target effects increase with lipophilicity [1679].)”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1679]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“Overall oral bioavailability depends not just on absorption but also on dissolution, gut transit time and first-pass metabolism, so it is perhaps surprising that rat bioavailability can be categorized by simple physical properties such as PSA and rotatable bond”
BackgroundLead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199 · cited 1×
“jpg" NDATA ITEM> ]> Ten years have passed since the publication of the 'rule of five' physical property guidelines for drug permeabilit”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Budavari, S. (1998) · Royal Society of Chemistry eBooks · Cited by 2,741
ADMET in silico modelling: towards prediction paradise?
van de Waterbeemd, H., & Gifford, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1032 · Cited by 1,863
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020 · cited 1×
“, and number of rule-of-five violations, PSA and ionization stat”
BackgroundQuantitative approach to biochemical structure-activity relationships
Hansch, C. (1969) · Accounts of Chemical Research · doi:10.1021/ar50020a002 · Cited by 918 · cited 1×
“This is not surprising: the role of LogP in influencing drug potency, pharmacokinetics and toxicity has been established for many year”
BackgroundMolecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877 · cited 1×
“This allows the processes of chemical optimization, which frequently increase physical propertie”
Background
Research works printed but not linked: 3
- Kubinyi, H. Lipophilicity and biological activity. Drug transport and drug distribution in model systems and in biological systems. Arzn. Forsch. 29, 1067–1080 (1979).
- Wood, A. Annual Reports in Medicinal Chemistry Volume 41 503–522 (Academic Press, Burlington, 2006).
- Gray, N. Changing Landscapes: A Special Report on the World's Top 50 Pharma Companies. Pharmaceutical Executive web site [online] , (2006)
Cited by
Items 401–500 of 1,006
Rackham, M. D., Brannigan, J. A., Rangachari, K., Meister, S., Wilkinson, A. J., Holder, A. A., Leatherbarrow, R. J., & Tate, E. W. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500066b · Cited by 80
Matched Molecular Pair Analysis: Significance and the Impact of Experimental Uncertainty
Krämer, C., Fuchs, J. E., Whitebread, S., Gedeck, P., & Liedl, K. R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500317a · Cited by 77
Leitstruktur‐orientierte Synthese: eine Alternative für die Synthesechemie
Nadin, A. J., Hattotuwagama, C. K., & Churcher, I. (2012) · Angewandte Chemie · doi:10.1002/ange.201105840 · Cited by 75
Cheng, H., Bagrodia, S., Bailey, S., Edwards, M. P., Hoffman, J. E., Hu, Q., Kania, R. S., Knighton, D. R., Marx, M. A., Ninkovic, S., et al. (2010) · MedChemComm · doi:10.1039/c0md00072h · Cited by 74
Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton’s Tyrosine Kinase
Smith, C. R., Dougan, D. R., Komandla, M., Kanouni, T., Knight, B., Lawson, J. D., Sabat, M. P., Taylor, E. R., Vu, P. H., & Wyrick, C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00734 · Cited by 75
Zerroug, A., Belaıdı, S., BENBRAHİM, İ., Sinha, L., & Chtita, S. (2018) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2018.03.024 · Cited by 78
DrugMetric: quantitative drug-likeness scoring based on chemical space distance
Li, B., Wang, Z., Liu, Z., Tao, Y., Sha, C., He, M., & Li, X. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae321 · Cited by 84
“This indicator helps to screen out compounds that may fail in clinical trials at an early stage,which is significant for increasing the success rate of drug development and reducing costs [1, 2].”
BackgroundAbdi, M. H., Beswick, P., Billinton, A., Chambers, L. J., Charlton, A., Collins, S. D., Collis, K. L., Dean, D. K., Fonfría, E., Gleave, R. J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.07.033 · Cited by 75
Tanaka, D., Tsuda, Y., Shiyama, T., Nishimura, T., Chiyo, N., Tominaga, Y., Sawada, N., Mimoto, T., & Kusunose, N. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101273e · Cited by 74
Direct Renin Inhibitors as a New Therapy for Hypertension
Webb, R. L., Schiering, N., Sedrani, R. C., & Maibaum, J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901885s · Cited by 81
Fernández‐Álvaro, E., Hong, W. D., Nixon, G. L., O’Neill, P. M., & Calderón, F. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01485 · Cited by 76
Scarim, C. B., Jornada, D. H., Machado, M. G. M., Ferreira, C. M. R., dos Santos, J. L., & Chung, M. C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.013 · Cited by 74
Bhattacharya, S. K., Andrews, K., Beveridge, R., Cameron, K. O., Chen, C., Dunn, M., Fernando, D., Gao, H., Hepworth, D., Jackson, V. M., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400473x · Cited by 73
Borhade, S. R., Svensson, R., Brandt, P., Artursson, P., Arvidsson, P. I., & Sandström, A. (2015) · ChemMedChem · doi:10.1002/cmdc.201402497 · Cited by 73
Fragment-to-Lead Medicinal Chemistry Publications in 2019
Jahnke, W., Erlanson, D. A., de Esch, I. J. P., Johnson, C. N., Mortenson, P. N., Ochi, Y., & Urushima, T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01608 · Cited by 76
Structure-Based Drug Design for G Protein-Coupled Receptors
Congreve, M., Dias, J. M., & Marshall, F. H. (2014) · Progress in medicinal chemistry · doi:10.1016/b978-0-444-63380-4.00001-9 · Cited by 75
Thermodynamics of Fragment Binding
Ferenczy, G. G., & Keserű, G. M. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200608b · Cited by 75
Hao, C., Zhao, F., Song, H., Guo, J., Li, X., Jiang, X., Huan, R., Song, S., Zhang, Q., Wang, R., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01342 · Cited by 73
Fixierung cyclischer Peptide: Mimetika von Proteinstrukturmotiven
Hill, T. A., Shepherd, N. E., Diness, F., & Fairlie, D. P. (2014) · Angewandte Chemie · doi:10.1002/ange.201401058 · Cited by 74
Patel, S. D., Meilandt, W. J., Erickson, R. I., Chen, J., Deshmukh, G. S., Estrada, A. A., Fuji, R. N., Gibbons, P., Gustafson, A. E., Harris, S. F., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00843 · Cited by 77
The development of small-molecule inhibitors targeting HPK1
Zhou, L., Wang, T., Zhang, K., Zhang, X., & Jiang, S. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114819 · Cited by 72
Aqueous solubility: Simple predictive methods (in silico, in vitro and bio-relevant approaches)
Elder, D. P., & Holm, R. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.10.041 · Cited by 72
Kung, P., Rui, E. Y., Bergqvist, S., Bingham, P., Braganza, J., Collins, M. R., Cui, M., Diehl, W. C., Dinh, D. M., Fan, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00515 · Cited by 75
Kundu, B., Das, S., Chowdhuri, S. P., Pal, S., Sarkar, D., Ghosh, A., Mukherjee, A., Bhattacharya, D., Das, B. B., & Talukdar, A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01938 · Cited by 75
Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists
Fauber, B. P., Gobbi, A., Robarge, K. D., Zhou, A., Barnard, A., Cao, J., Deng, Y., Eidenschenk, C., Everett, C., Ganguli, A., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.055 · Cited by 75
Kumar, S. A., Kumar, T. D. A., Beeraka, N. M., Pujar, G. V., Singh, M., Akshatha, H. S., & Bhagyalalitha, M. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0243 · Cited by 95
Tiew, K.-C., Dou, D., TERAMOTO, T., Lai, H., Alliston, K. R., Lushington, G. H., Padmanabhan, R., & Groutas, W. C. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.047 · Cited by 71
Christiansen, E., Hansen, S. V. F., Urban, C., Hudson, B. D., Wargent, E. T., Grundmann, M., Jenkins, L., Zaibi, M. S., Stocker, C. J., Ullrich, S., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000673 · Cited by 74
“10 When adding larger substituents on the terminal ring of the alkyne ligands, the meta -substituted compounds ( 18 and 20 ) were found to be favored over the ortho analogues ( 17 and 19 ).”
A unified lead-oriented synthesis of over fifty molecular scaffolds
Doveston, R. G., Tosatti, P., Dow, M., Foley, D. J., Li, H. Y., Campbell, A. J., House, D., Churcher, I., Marsden, S. P., & Nelson, A. S. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob02287d · Cited by 74
Structurally Enabled Discovery of Adenosine A 2A Receptor Antagonists
Jazayeri, A., Andrews, S. P., & Marshall, F. H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00119 · Cited by 83
Computational Prediction of Drug Solubility in Fasted Simulated and Aspirated Human Intestinal Fluid
Fagerberg, J. H., Karlsson, Ε., Ulander, J., Hanisch, G., & Bergström, C. A. S. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1487-z · Cited by 70
“This is in spite of their poor aqueous solubility [1–4], the increased awareness of related problems and the multitude of mnemonic rules for avoiding these compounds with low or variable absorption and pharmacokinetics [5–7].”
BackgroundInnovations in Oral Therapies for Inflammatory Bowel Disease
Ma, C., Battat, R. J., Dulai, P. S., Parker, C. E., Sandborn, W. J., Feagan, B. G., & Jairath, V. (2019) · Drugs · doi:10.1007/s40265-019-01169-y · Cited by 73
Using Physicochemical Measurements to Influence Better Compound Design
Bunally, S. B., Luscombe, C. N., & Young, R. J. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219859845 · Cited by 78
Wang, D., Yin, F., Li, Z., Zhang, Y., & Chen, S. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03277-2 · Cited by 82
“A small molecule is considered “drug-like” and orally bioavailable if it adheres to Lipinski’s Rule of 5 (Ro5), which stipulates specific criteria for molecular weight, hydrogen bond donors, hydrogen bond acceptors, and log P [163, 164].”
Shultz, M. D., Kirby, C. A., Stams, T., Chin, D. N., Blank, J., Charlat, O., Cheng, H., Cheung, A. K., Cong, F., Feng, Y., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2011222 · Cited by 69
Munuganti, R. S. N., Hassona, M. D. H., Leblanc, E., Frewin, K., Singh, K., Ma, D., Ban, F., Hsing, M., Adomat, H. H., Lallous, N., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.012 · Cited by 76
Thermodynamic Optimisation in Drug Discovery: A Case Study using Carbonic Anhydrase Inhibitors
Scott, A. D., Phillips, C., Alex, A., Flocco, M. M., Bent, A., Randall, A., O’Brien, R., Damian, L., & Jones, L. H. (2009) · ChemMedChem · doi:10.1002/cmdc.200900386 · Cited by 75
Hudkins, R. L., Raddatz, R., Tao, M., Mathiasen, J. R., Aimone, L. D., Becknell, N. C., Prouty, C. P., Knutsen, L. J. S., Yazdanian, M. A., Moachon, G., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200401v · Cited by 69
Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms
Lambert, M. N. T., Thorup, A. C. S., Hansen, E. S. S., & Jeppesen, P. B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176590 · Cited by 80
Hoffer, L., Voitovich, Y. V., Raux, B., Carrasco, K., Muller, C., Fedorov, A. Y., Derviaux, C., Amouric, A., Betzi, S., Horvath, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00653 · Cited by 75
Fragment-to-Lead Medicinal Chemistry Publications in 2017
Mortenson, P. N., Erlanson, D. A., de Esch, I. J. P., Jahnke, W., & Johnson, C. N. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01472 · Cited by 69
Mind and machine in drug design
Schneider, G. (2019) · Nature Machine Intelligence · doi:10.1038/s42256-019-0030-7 · Cited by 73
Beyond the Flavour: The Potential Druggability of Chemosensory G Protein-Coupled Receptors
Pizio, A. D., Behrens, M., & Krautwurst, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061402 · Cited by 76
“like compounds helps alleviate attrition rates in drug discovery [146].”
BackgroundSalim, R., Ech-chihbi, E., Fernine, Y., Koudad, M., Guo, L., Berdimurodov, E. T., Azam, M., Rais, Z., & Taleb, M. (2023) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2023.123579 · Cited by 68
CD36-mediated endocytosis of proteolysis-targeting chimeras
Wang, Z., Pan, B., Manne, R., Chen, J., Lv, D., Wang, M., Tran, P., Weldemichael, T., Yan, W., Zhou, H., et al. (2025) · Cell · doi:10.1016/j.cell.2025.03.036 · Cited by 75
Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies
Greene, N., Aleo, M. D., Louise‐May, S., Price, D. A., & Will, Y. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.129 · Cited by 69
Emerging technologies for metabolite generation and structural diversification
Cusack, K. P., Koolman, H. F., Lange, U. E. W., Peltier, H. M., Piel, I., & Vasudevan, A. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.003 · Cited by 69
Ingólfsson, H. I., & Andersen, O. S. (2010) · Assay and Drug Development Technologies · doi:10.1089/adt.2009.0250 · Cited by 68
A Leap into the Chemical Space of Protein-Protein Interaction Inhibitors
Villoutreix, B. O., Labbé, C. M., Lagorce, D., Laconde, G., & Spérandio, O. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802651571 · Cited by 74
Design and evaluation of novel glutaminase inhibitors
McDermott, L. A., Iyer, P. C., Vernetti, L., Rimer, S., Sun, J., Boby, M. L., Yang, T., Fioravanti, M., O’Neill, J., Wang, L., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.009 · Cited by 72
Fairoosa, J., Neetha, M., & Anilkumar, G. N. (2021) · RSC Advances · doi:10.1039/d0ra10472h · Cited by 68
Del Amo, L., Cano, A., Ettcheto, M., Souto, E. B., Espina, M., Camins, A., García, M. L., & Sánchez-López, E. (2021) · Applied Sciences · doi:10.3390/app11094305 · Cited by 67
“Thus, structural modification of the drug to increase its affinity to endogenous transport proteins on the cerebellar endothelium has been proposed [64].”
BackgroundBoraei, A. T. A., Eltamany, E. H. M., Ali, I. A. I., Gebriel, S. M., & Nafie, M. S. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104877 · Cited by 67
Elhady, S. S., Abdelhameed, R. F. A., Malatani, R. T., Alahdal, A. M., Bogari, H. A., Almalki, A. J., Mohammad, K. A., Ahmed, S. A., Khedr, A. I. M., & Darwish, K. M. (2021) · Biology · doi:10.3390/biology10050389 · Cited by 68
“Compounds with molecular descriptors/properties showing fewer, and preferably no, violations of both rules are more likely to be orally available and exhibit lower attrition rates throughout clinical trials [88,89].”
BackgroundXie, H., Li, C., Tang, H., Tandon, I., Liao, J., Roberts, B. L., Zhao, Y. Q., & Tang, W. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01941 · Cited by 71
Cregg, J., Pota, K., Tomlinson, A. C. A., Yano, J. K., Marquez, A., Liu, Y., Schulze, C. J., Seamon, K. J., Holderfield, M. T., Wei, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02313 · Cited by 78
Zak, M., Hurley, C. A., Ward, S. I., Bergeron, P., Barrett, K., Balázs, M., Blair, W. S., Bull, R., Chakravarty, P., Chang, C. C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4004895 · Cited by 67
Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors
Johannes, J. W., Bates, S. M., Beigie, C., Belmonte, M. A., Breen, J. N., Cao, S., Centrella, P. A., Clark, M., Cuozzo, J. W., Dumelin, C. E., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00464 · Cited by 67
Christiansen, E., Urban, C., Grundmann, M., Due‐Hansen, M. E., Hagesæther, E., Schmidt, J., Pardo, L., Ullrich, S., Kostenis, E., Kassack, M. U., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2005699 · Cited by 69
Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
Roskoski, R. J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106156 · Cited by 70
Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain
Unzue, A., Xu, M., Dong, J., Wiedmer, L., Spiliotopoulos, D., Caflisch, A., & Nevado, C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00172 · Cited by 66
Engers, J. L., Rodriguez, A. L., Konkol, L. C., Morrison, R. D., Thompson, A. D., Byers, F. W., Blobaum, A. L., Chang, S., Venable, D. F., Loch, M. T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01005 · Cited by 68
Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors
Terao, Y., Suzuki, H., Yoshikawa, M., Yashiro, H., Takekawa, S., Fujitani, Y., Okada, K., Inoue, Y., Yamamoto, Y., Nakagawa, H., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.084 · Cited by 66
Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc
Fauber, B. P., Boenig, G. D. L., Burton, B., Eidenschenk, C., Everett, C., Gobbi, A., Hymowitz, S. G., Johnson, A. R., Liimatta, M. B., Lockey, P. M., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.10.054 · Cited by 66
P2X receptor antagonists for pain management: examination of binding and physicochemical properties
Gum, R. J., Wakefield, B. D., & Jarvis, M. F. (2011) · Purinergic Signalling · doi:10.1007/s11302-011-9272-5 · Cited by 68
“One noticeable trend during this timeframe is that the molecular weight and lipophilicity of molecules entering clinical studies has continued to increase [15].”
Andersson, S., Armstrong, A., Björe, A., Bowker, S., Chapman, S. F., Davies, R., Donald, C. S., Egner, B. J., Elebring, T., Holmqvist, S., et al. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.03.005 · Cited by 66
Fragment-to-Lead Medicinal Chemistry Publications in 2015
Johnson, C. N., Erlanson, D. A., Murray, C. W., & Rees, D. C. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01123 · Cited by 66
Song, T., Ren, P. R., Ma, Z.-M., Xiao, J., & Yang, Y. (2019) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.9b05298 · Cited by 66
Drug safety testing paradigm, current progress and future challenges: an overview
Ahuja, V., & Sharma, S. C. (2013) · Journal of Applied Toxicology · doi:10.1002/jat.2935 · Cited by 73
Bugge, S., Kaspersen, S. J., Larsen, S., Nonstad, U., Bjørkøy, G., Sundby, E., & Hoff, B. H. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.042 · Cited by 68
Hanan, E. J., Eigenbrot, C. W., Bryan, M. C., Burdick, D. J., Chan, B. K., Chen, Y., Dotson, J., Heald, R. A., Jackson, P. S., La, H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501578n · Cited by 67
Kogej, T., Blomberg, N., Greasley, P. J., Mundt, S. M., Vainio, M. J., Schamberger, J., Schmidt, G. P., & Hüser, J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.011 · Cited by 68
Koike, T., Takai, T., Hoashi, Y., Nakayama, M., Kosugi, Y., Nakashima, M., Yoshikubo, S.-I., Hirai, K., & Uchikawa, O. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200385u · Cited by 65
Zender, M., Klein, T., Henn, C., Kirsch, B., Maurer, C. K., Kail, D., Ritter, C., Dolezal, O., Steinbach, A., & Hartmann, R. W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400830r · Cited by 71
Polêto, M. D., Rusu, V. H., Grisci, B. I., Dorn, M., Lins, R. D., & Verli, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00395 · Cited by 76
“Also, recent reviews have shown an increase of molar mass in the recent medicinal chemistry efforts (Leeson and Springthorpe, 2007) andmany authors correlate this strategy with the likelihood of poor results of such compounds (Gleeson, 2008;Waring, 2009, 2010; Gleeson et al.”
ResultGriffith, D. A., Hadcock, J. R., Black, S. C., Iredale, P. A., Carpino, P. A., DaSilva-Jardine, P. A., Day, R. F., DiBrino, J., Dow, R. L., Landis, M. S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8012932 · Cited by 66
Castanedo, G. M., Blaquière, N., Beresini, M. H., Bravo, B. J., Brightbill, H. D., Chen, J., Cui, H., Eigenbrot, C. W., Everett, C., Feng, J. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01363 · Cited by 70
Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα
Borsari, C., Keleş, E., McPhail, J. A., Schäfer, A., Sriramaratnam, R., Goch, W., Schaefer, T., Pascale, M. D., Bal, W., Gstaiger, M., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c13568 · Cited by 70
How Are Fragments Optimized? A Retrospective Analysis of 145 Fragment Optimizations
Ferenczy, G. G., & Keserű, G. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301851v · Cited by 64
Zhang, Y., Jin, Y., Wang, L., Zhang, Q., Meng, C., & Duan, C. (2021) · Green Chemistry · doi:10.1039/d1gc02670d · Cited by 63
Structural Insights into the Molecular Basis of the Ligand Promiscuity
Sturm, N., Desaphy, J., Quinn, R. J., Rognan, D., & Kellenberger, E. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300196g · Cited by 67
AqF026 Is a Pharmacologic Agonist of the Water Channel Aquaporin-1
Yool, A. J., Morelle, J., Cnops, Y., Verbavatz, J., Campbell, E. M., Beckett, E. A. H., Booker, G. W., Flynn, G. A., & Devuyst, O. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012080869 · Cited by 63
Heald, R. A., Bowman, K. K., Bryan, M. C., Burdick, D. J., Chan, B. K., Chan, E. W., Chen, Y., Clausen, S., Dominguez‐Fernandez, B., Eigenbrot, C. W., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01412 · Cited by 63
Price-Focused Analysis of Commercially Available Building Blocks for Combinatorial Library Synthesis
Kalliokoski, T. (2015) · ACS Combinatorial Science · doi:10.1021/acscombsci.5b00063 · Cited by 63
Investigation of the Relationship between Topology and Selectivity for Druglike Molecules
Yang, Y., Chen, H., Nilsson, I., Mureşan, S., & Engkvist, O. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1008456 · Cited by 63
Fauber, B. P., René, O., Deng, Y., DeVoss, J., Eidenschenk, C., Everett, C., Ganguli, A., Gobbi, A., Hawkins, J., Johnson, A. R., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00597 · Cited by 70
Alagumuthu, M., & Arumugam, S. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.01.007 · Cited by 63
Yukawa, T., & Naven, R. T. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00536 · Cited by 68
Electrostatic Complementarity in Structure-Based Drug Design
Cons, B. D., Twigg, D. G., Kumar, R., & Chessari, G. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00164 · Cited by 68
Xie, X., Liu, Y., Liu, G., Zhao, Y., Bian, J., Li, Y. H., Zhang, J., Wang, X., & Tang, B. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01758 · Cited by 62
Ligand efficiency metrics considered harmful
Kenny, P. W., Leitão, A., & Montanari, C. A. (2014) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-014-9757-8 · Cited by 66
“The H2014 study asserts that ‘‘LLE correlates positively with the drug efficiency index (DEI)’’ [1].”
BackgroundMethodInfluentialValidation of Early Human Dose Prediction: A Key Metric for Compound Progression in Drug Discovery
Page, K. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00840 · Cited by 64
Patel, S. D., Harris, S. F., Gibbons, P., Deshmukh, G. S., Gustafson, A. E., Kellar, T., Lin, H., Liu, X., Liu, Y., Liu, Y., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01072 · Cited by 63
Fragment-to-Lead Medicinal Chemistry Publications in 2016
Johnson, C. N., Erlanson, D. A., Jahnke, W., Mortenson, P. N., & Rees, D. C. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01298 · Cited by 62
Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
Fonseca, A., Reis, J., Silva, T., Matos, M. J., Bagetta, D., Ortuso, F., Alcaro, S., Uriarte, E., & Borges, F. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00918 · Cited by 62
Hodges, T. R., Abbott, J. R., Little, A. J., Sarkar, D., Salovich, J. M., Howes, J. E., Akan, D. T., Sai, J., Arnold, A. L., Browning, C. F., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01108 · Cited by 62
Bhardwaj, V. K., SINGH, R. K., Sharma, J., Das, P., & Purohit, R. (2020) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2020.105494 · Cited by 61
Drug-likeness scoring based on unsupervised learning
Lee, K.-H., Jang, J., Seo, S., Lim, J., & Kim, W. Y. (2021) · Chemical Science · doi:10.1039/d1sc05248a · Cited by 74
Soares, J. X., Santos, Á., Fernandes, C., & Pinto, M. M. M. (2022) · Chemosensors · doi:10.3390/chemosensors10080340 · Cited by 71
Scott, J. S., Bowker, S. S., deSchoolmeester, J., Gerhardt, S., Hargreaves, D., Kilgour, E., Lloyd, A., Mayers, R. M., McCoull, W., Newcombe, N. J., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300592r · Cited by 61
Metadata
- Authors
- Leeson, P. D., & Springthorpe, B.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Leeson, Paul D.
- ORCID
- Leeson, Paul D.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-11
- Volume
- 6
- Issue
- 11
- Pages
- 881-890
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2062458432
- Cited by
- 2,403
- References
- 60
- Citations by year
- 2026: 143 · 2025: 113 · 2024: 140 · 2023: 127 · 2022: 104 · 2021: 144 · 2020: 105 · 2019: 146 · 2018: 119 · 2017: 140 · 2016: 145 · 2015: 140 · 2014: 151 · 2013: 160 · 2012: 165
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Merck
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- drug-likeness, Lipinski's rule of five, lipophilicity, drug attrition, drug discovery, drug selectivity
- MeSH terms
- Chemistry, Pharmaceutical, Decision Making, Pharmaceutical Preparations, Humans, Water, 1-Octanol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.